Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2008

Serenex and CHDI Ally to Evaluate Treatments for Huntington’s

  • Serenex and CHDI entered into an agreement to assess the former’s drug candidates for the treatment of Huntington’s disease. CHDI will evaluate a number of Serenex’ small molecule, brain-penetrating, orally bioavailable Hsp90 inhibitors.

    Under the terms of the agreement, Serenex will retain all rights to develop and commercialize investigated molecules. The company discovered these Hsp90 inhibitors using its chemoproteomics platform.

    “The root cause of several neurodegenerative diseases such as HD is improper protein processing, which results in the aggregation of mutant or incorrectly folded proteins,” explains Richard Kent, M.D., president and CEO of Serenex. “Inhibition of Hsp90 destabilizes these proteins, targets them for degradation, and thus prevents the protein aggregates from forming.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »